Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash & Equivalents (2021 - 2025)

ARS Pharmaceuticals' Cash & Equivalents history spans 5 years, with the latest figure at $41.3 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 18.69% year-over-year to $41.3 million; the TTM value through Dec 2025 reached $41.3 million, down 18.69%, while the annual FY2025 figure was $41.3 million, 18.69% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $41.3 million at ARS Pharmaceuticals, down from $59.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $374.2 million in Q1 2021 and bottomed at $36.6 million in Q2 2024.
  • The 5-year median for Cash & Equivalents is $65.8 million (2023), against an average of $133.7 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 250.5% in 2022 before it tumbled 70.21% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $60.1 million in 2021, then surged by 250.5% to $210.5 million in 2022, then crashed by 66.29% to $71.0 million in 2023, then dropped by 28.4% to $50.8 million in 2024, then decreased by 18.69% to $41.3 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Cash & Equivalents are $41.3 million (Q4 2025), $59.6 million (Q3 2025), and $51.5 million (Q2 2025).